ArticleFrontiers in immunology2026
HDAC8 impairs tight junctions in allergic rhinitis through Smad7 deacetylation.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Allergic rhinitis (AR) involves Th2/Th17 immune dysregulation and nasal epithelial barrier dysfunction; however, the molecular mechanisms linking these processes remain unclear. Objective: Here, we investigated whether histone deacetylase 8 (HDAC8) contributes to tight junction (TJ) disruption in AR by modulating Smad7 acetylation. Methods: Primary human nasal epithelial cells and a house dust mite-induced AR mouse model were used in the study. HDAC8 was modulated via overexpression, siRNA knockdown, or pharmacological inhibition (PCI-34051). Smad7 function was assessed using wild-type and acetylation-mimetic (K64/70Q) mutants. Protein interactions and expression levels of HDAC8, Smad7, acetyl-Smad7, and TJ proteins (ZO-1, Occludin, Claudin-1) were analyzed by co-immunoprecipitation and western blot. Nasal pathology and serum cytokines were evaluated by histology and ELISA, respectively. Results: In AR mouse models, HDAC8 expression was upregulated and showed enhanced binding to Smad7, accompanied by reduced Smad7 acetylation and decreased TJ protein expression. PCI-34051 treatment or HDAC8 knockdown restored Smad7 acetylation and TJ protein expression. Notably, the acetylation-mimetic Smad7 mutant rescued HDAC8-induced TJ disruption, suggesting that Smad7 acetylation status is involved in this effect. Conclusion: These findings support that HDAC8-mediated reduction of Smad7 acetylation contributes to epithelial barrier dysfunction in AR, highlighting HDAC8 as a potential therapeutic target for restoring mucosal homeostasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.